NOVOMEDLINK™

This page contains information about Novo Nordisk products.

Effective A1C reductions with NovoLog® Mix 70/301,2

The IMPROVE™ study: initiating, adding, or converting to NovoLog® Mix 70/30 (global cohort)2

A1C reductions with NovoLog® Mix 70/30

Results from patients who completed the IMPROVE™ study and had A1C values available at baseline and final visit. The IMPROVE™ study is a multinational, open-label, nonrandomized, 26-week, observational study evaluating the safety and efficacy of NovoLog® Mix 70/30 in patients with type 2 diabetes.1

  • Major hypoglycemia decreased by 91% (values based on patient recall)2

The IMPROVE™ study: converting from human premix to NovoLog® Mix 70/30 (insulin cohort)3

A1C reduction when converting from human premix to NovoLog® Mix 70/30

Results from patients who completed the IMPROVE™ study who were previously treated with human premix ± OAD therapy and had A1C values available at baseline and final visit. The IMPROVE study is a multinational, open-label, nonrandomized, 26-week, observational study evaluating the safety and efficacy of NovoLog® Mix 70/30 in patients with type 2 diabetes.3

The 1-2-3 study:

1, 2, and 3 daily doses: reaching A1C goal with NovoLog® Mix 70/30

In a separate study, one, two, and three daily doses helped the majority of patients get to A1C goal of <7%. A once-daily dose at dinner helped 41% of patients achieve A1C goal, an additional dose at breakfast helped 70% of patients achieve A1C goal, and an additional third dose at lunchtime helped 77% of patients achieve A1C goal.4

NovoLog® Mix 70/30 efficacy with up to three daily doses

A 48-week, open-label, observational study in 100 patients 18 years and older with type 2 diabetes for 12 months and A1C levels between 7.5% and 10%. Patients had been previously treated on a stable antidiabetic regimen for at least 3 months. NovoLog® Mix 70/30 was initiated once daily during phase 1 and titrated in phases to dosing schedules of BID (phase 2) and TID (phase 3) as needed to reach treatment goals. Subjects achieving an A1C level of 6.5% were considered to have completed the study. Patients not achieving an A1C level of 6.5% continued to phase 3. Results include phases 1, 2, and 3.4

Each time the dosing schedule was titrated, NovoLog® Mix 70/30 provided additional benefits without an increase in major hypoglycemia.4

Along with A1C reductions, see how PPG and FPG improvements were observed when converting to NovoLog® Mix 70/30.5,6

Formulary lookup

References:

  1. Khutsoane D, Sharma SK, Almustafa M, et al; for the PRESENT Study Group. Biphasic insulin aspart 30 treatment improves glycaemic control in patients with type 2 diabetes in a clinical practice setting: experience from the PRESENT study. Diabetes Obes Metab. 2008;10(3):212-222.
  2. Valensi P, Benroubi M, Borzi V, et al, on behalf of IMPROVE™ Study Group Expert Panel. The IMPROVE™ study—a multinational, observational study in type 2 diabetes: baseline characteristics from eight national cohorts. Int J Clin Pract. 2008;62(11):1809-1819.
  3. Shah S, Benroubi M, Borzi V, et al, on behalf of the IMPROVE™ Study Group Expert Panel. Safety and effectiveness of biphasic insulin aspart 30⁄70 (NovoMix® 30) when switching from human premix insulin in patients with type 2 diabetes: subgroup analysis from the 6-month IMPROVE™ observational study. Int J Clin Pract. 2009;63(4):574-582.
  4. Garber AJ, Wahlen J, Wahl T, et al. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (the 1-2-3 study). Diabetes Obes Metab. 2006;8(1):58-66.
  5. Shestakova M, Sharma SK, Almustafa M, et al. Transferring type 2 diabetes patients with uncontrolled glycaemia from biphasic human insulin to biphasic insulin aspart 30: experiences from the PRESENT study. Curr Med Res Opin. 2007;23(12):3209-3214.
  6. Data on file, Novo Nordisk, Inc., Princeton, NJ.

  1. NovoLog® Mix 70/30 (70% insulin aspart protamine suspension and 30% insulin aspart injection, [rDNA origin]) Indications and Usage

    NovoLog® Mix 70/30 (70% insulin aspart protamine suspension and 30% insulin aspart injection, [rDNA origin]) is an insulin analog indicated to improve glycemic control in patients with diabetes mellitus.

    Important Limitations of Use:
    In premix insulins, such as NovoLog® Mix 70/30, the proportions of rapid acting and long acting insulins are fixed and do not allow for basal versus prandial dose adjustments.

    NovoLog® Mix 70/30 Important Safety Information

    NovoLog® Mix 70/30 is contraindicated during episodes of hypoglycemia and in patients hypersensitive to NovoLog® Mix 70/30 or one of its excipients.

    NovoLog® Mix 70/30 has a faster onset of action than human insulin premix 70/30 and should be dosed within 15 minutes before meal initiation for patients with type 1 diabetes. For patients with type 2 diabetes, dosing should occur within 15 minutes before or after meal initiation.

    NovoLog® Mix 70/30 should not be administered intravenously or used in insulin infusion pumps. NovoLog® Mix 70/30 should not be mixed with any other insulin product.

    Hypoglycemia is the most common adverse effect of insulin therapy, including NovoLog® Mix 70/30. The timing of hypoglycemia may reflect the time-action profile of the insulin formulation. Glucose monitoring is recommended for all patients with diabetes. Any change of insulin should be made cautiously and only under medical supervision.

    Needles and NovoLog® Mix 70/30 FlexPen® must not be shared.

    Severe, life-threatening generalized allergy, including anaphylaxis, may occur with insulin products, including NovoLog® Mix 70/30. Adverse reactions observed with NovoLog® Mix 70/30 include hypoglycemia, allergic reactions, local injection site reactions, lipodystrophy, rash, and pruritus. Insulin, particularly when given in settings of poor glycemic control, may cause hypokalemia. Like all insulins, NovoLog® Mix 70/30 requirements may be reduced in patients with renal impairment or hepatic impairment.

    The safety and effectiveness of NovoLog® Mix 70/30 has not been established in pediatric patients. Clinical studies of NovoLog® Mix 70/30 did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently than younger patients.

    Please see Prescribing InformationPrescribing Information.

FlexPen® and NovoLog® are registered trademarks of Novo Nordisk A/S. NovoMedLink™ is a trademark of Novo Nordisk A/S.